| Features: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Chemical that dissolves many substances that can affect the body. It is used for bladder inflammation, limb pain, and IV leakage, but it can also cause side effects and interact with other drugs. Dimethyl sulfoxide — DMSO is a small, highly polar organosulfur compound with the formula (CH3)2SO. It is formally classified as a polar aprotic solvent, membrane-permeability enhancer, cryoprotectant and pharmaceutical excipient; concentrated DMSO also has direct biological activity. Standard abbreviations are DMSO and Me2SO. Commercial DMSO is produced by oxidation of dimethyl sulfide, historically obtained as a kraft-pulping by-product. In cancer research, DMSO is primarily a solvent and experimental differentiation agent rather than a clinically established anticancer drug. Its biological effects are strongly concentration-, exposure-time-, cell-type- and formulation-dependent. Primary mechanisms (ranked):
Bioavailability / PK relevance: DMSO is rapidly absorbed across skin and biological membranes and distributes widely into tissues and body fluids. It is metabolized primarily to dimethyl sulfone and dimethyl sulfide; metabolites are eliminated through urine, feces, breath and skin. Systemic exposure can produce a characteristic garlic-like taste and odour. DMSO also increases tissue penetration of other chemicals, so pharmaceutical purity and control of contaminants are critical. In-vitro vs systemic exposure relevance: Most cancer differentiation, growth-arrest and cytotoxicity studies use approximately 0.5–2.5% DMSO, equivalent to roughly 70–350 mM. These sustained concentrations are generally not representative of safe systemic anticancer exposure. DMSO concentrations routinely treated as an inert vehicle can themselves alter membranes, transcription, metabolism, proliferation and drug responses; solvent controls must therefore use the lowest feasible concentration, commonly at or below 0.1%, with cell-specific validation. Clinical evidence status: Cancer evidence is predominantly preclinical and includes older leukemia-differentiation models and diverse cell-culture observations. DMSO has no established role as systemic or topical anticancer monotherapy and is not supported by anticancer RCT evidence. Its clinically recognized roles are intravesical symptomatic treatment of interstitial cystitis, cryopreservation of cells and tissues, and use as a penetration-enhancing pharmaceutical excipient. In oncology it is more relevant as a solvent, delivery vehicle, cryoprotectant and potential modifier of treatment response than as an active anticancer therapy. Mechanistic effects of dimethyl sulfoxide
P: 0–30 min R: 30 min–3 hr G: >3 hr |
| Source: |
| Type: |
| cryoprotectant: protect freeze thaw damage |
| 6725- | DMSO, | DMSO induces dehydration near lipid membrane surfaces |
| - | Study, | Nor, | NA |
| 6728- | DMSO, | Molecular basis for dimethylsulfoxide (DMSO) action on lipid membranes |
| - | in-vitro, | Nor, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:72 Target#:1488 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid